A surgical brow lift physically raises the forehead tissue. A Botox® brow lift gets at a similar idea from the opposite direction: instead of pulling the brow up, it relaxes the muscles that are pulling it down. Nothing is tightened and nothing is added. The brow moves because the balance of force around it changes, which is why understanding the anatomy behind each Botox® injection site matters more here than almost anywhere else on the face.
It is also why the results are more modest and more specific than most before-and-after galleries suggest. The published evidence points to one dependable outcome — a lift at the tail of the brow — and one common misconception, which is that treating the forehead lifts the whole eyebrow. It does not. It usually does the opposite.
This guide covers what actually moves, where the injections go, how many units the literature supports, how long it lasts, who is a poor candidate, and what can go wrong.
Think of the eyebrow as the rope in a tug-of-war. One team pulls up. The other team pulls down. Botulinum toxin does not grab the rope — it sends players home. Whichever team loses players, the rope moves the other way.
There is only one player on the "up" team. Everything else pulls down:
| Muscle | Which team | What it does to the brow |
|---|---|---|
| Frontalis | Elevator — the only one | Raises the brow; creates the horizontal forehead lines |
| Corrugator supercilii | Depressor | Pulls the brow down and inward; the main "eleven lines" muscle |
| Depressor supercilii | Depressor | Pulls the inner brow straight down |
| Procerus | Depressor | Pulls the inner brow down across the bridge of the nose |
| Orbicularis oculi (upper and outer fibres) | Depressor | Pulls the tail of the brow down — the target of a lateral brow lift |
That last row is the whole procedure in miniature. The upper-outer edge of the ring muscle around the eye is the only depressor sitting under the brow tail. Relax it, and the frontalis lifts that corner unopposed.
The published landmarks are specific, and they are the difference between a lifted brow and a dropped eyelid. The figures below come from the standard reference literature on botulinum toxin in the upper face and from the BOTOX® Cosmetic label itself.
| Target | What the literature specifies |
|---|---|
| Lateral brow lift | Approximately 8 to 10 units just inferior to the lateral eyebrow, weakening the superolateral orbicularis oculi so the frontalis elevates the tail unopposed |
| Depth and position | Orbicularis injections roughly 1 to 2 mm deep, about 1 cm lateral to the lateral orbital rim or lateral canthus |
| Frontalis safety line | At least 1.5 cm above the superior orbital rim, to reduce the risk of eyelid ptosis |
| Frontalis dose | Roughly 10 to 20 units in women and 20 to 30 in men — about half the glabellar dose |
| Lateral corrugator | FDA label: place lateral corrugator injections at least 1 cm above the bony supraorbital ridge |
The single most useful line on the label: "Treat forehead lines in conjunction with glabellar lines to minimize the potential for brow ptosis." Relaxing the forehead on its own removes the only muscle holding the brow up. If the frontalis is treated, the depressors have to come down with it. Our forehead Botox® dosing guide for beginners works through how that balance is planned dose by dose.
Partly — and the part matters. In a randomized controlled trial published in Plastic and Reconstructive Surgery, 45 patients (90 eyebrows) were divided into three groups. All three received toxin to both the inner and outer brow depressors; the forehead was then injected in a V pattern, a middle horizontal pattern, or a high horizontal pattern. Eyebrow position was measured from standardized photographs.
Two weeks later, in every group, the brow sat lower at every measured position except the lateral edge, which sat higher. The middle-forehead pattern lowered the brow more than the high pattern. The high pattern was less effective on forehead lines but prevented eyebrow ptosis.
Translated into a consultation: the outer third of the brow goes up, and the rest of the brow follows the forehead down. A patient expecting the whole brow to rise several millimetres is going to be disappointed, and telling them so before treatment is far easier than explaining it afterwards.
Hooding has more than one cause, and botulinum toxin only addresses one of them.
Where the hooding is caused by the eyelid itself rather than the brow, the presentation and the management are different again — see droopy eyelid after Botox® (ptosis) for how true blepharoptosis is recognised and managed.
There is no single number, and the number most often quoted has lost its context. The familiar "20 to 40 units" comes from a double-blind, dose-ranging randomized trial in which 79 women received 10, 20, 30 or 40 units into the glabella alone, across seven injection sites. Doses of 20 to 40 units produced an immediate rise at the outer brow, followed by central and inner elevation that peaked twelve weeks after treatment. The lowest dose, 10 units, produced mild brow ptosis — it dropped the brow instead of raising it.
Two different questions, two different doses
Published ranges, not a protocol. The glabellar figure is the dose-ranging trial above, in which 10 units lowered the brow. Every plan is set by assessment, not by table.
Assessment beats arithmetic for a measurable reason. An ultrasound study of 127 adults mapping the frontalis, procerus, corrugator and orbicularis found side-to-side differences of up to 40% in both muscle thickness and depth within the same face, with further variation by sex and body mass index. A patient whose brows sit at different heights is the rule rather than the exception, and the dose on each side should reflect that.
The timing is more interesting than a single "three to four months" figure suggests, and patients tend to find the detail reassuring.
A 2026 multicentre case series that measured brow position objectively found that roughly three quarters of the effect on brow position appeared within two days, peaking in the first 24 hours, with the exposed eyelid area up about 12% against baseline by day 30. At the other end, the dose-ranging trial above found the central and inner lift still building at twelve weeks. So the brow tail moves almost immediately; the rest of the effect matures slowly.
The change itself is measured in millimetres, not centimetres. Well-placed injections give a subtle, temporary lift — the startled look is a sign of an over-peaked lateral brow, not a successful treatment. Retreatment should not be scheduled closer than three months apart.
Good candidates usually have a brow tail that has descended with age, strong brow depressors, reasonable skin quality, and a realistic idea of what a few millimetres looks like. Patients with deep frown lines between the brows often do particularly well, because treating the glabellar complex is what produces the lift in the first place.
The list of poor candidates is shorter but more important, and it is the part most consumer pages leave out:
Brow work carries a complication that is the mirror image of the treatment: the brow goes the wrong way. These are not rare events in the product's own trial data.
| Outcome | Reported rate (BOTOX® Cosmetic trials) | What causes it |
|---|---|---|
| Brow ptosis | 2% (forehead lines) | Relaxing the frontalis without adequately treating the depressors, or dosing too low on the forehead |
| Eyelid ptosis | 2% (forehead lines); 3% (glabellar lines) | Product reaching the levator palpebrae — injecting too low, too deep, or too much volume |
| "Spock" / Mephisto brow | Not separately tabulated | The central forehead relaxed while the lateral frontalis keeps working; corrected with a small lateral top-up |
| Bruising, tenderness, headache | Common, self-limiting | Ordinary injection effects |
| Temporary asymmetry | Common, self-limiting | Underlying muscle asymmetry, uneven dosing or uneven diffusion |
Eyelid ptosis at 3% is worth stating plainly, because it is the most frequently reported adverse reaction for glabellar treatment — not a rarity. It typically resolves as the toxin wears off. The systematic approach to avoiding all of the above is covered in minimizing risks in forehead Botox® procedures.
All botulinum toxin products carry a boxed warning regarding the distant spread of toxin effect. Product should be sourced only through legitimate channels: the FDA has issued alerts about counterfeit botulinum toxin and, in November 2025, warning letters to 18 companies illegally marketing these products online.
No, and it is better to say so. BOTOX® Cosmetic is FDA-approved in adults for the temporary improvement in the appearance of four things only:
Repositioning the eyebrow is not among them. It is a well-established off-label use, which is legal and routine in aesthetic medicine, but it should be disclosed in consent and documented in the chart.
Most patients describe it as a brief pinch rather than pain — the needles are very fine and each injection takes a second or two. That said, the area around the eye is more sensitive than the forehead, and pain tolerance varies. Topical numbing cream applied about an hour beforehand, ice immediately before injection, and a slow injection technique all help. Tenderness for an hour or so afterwards is normal.
Three developments are worth knowing if you inject the upper face, and all three point the same direction — smaller doses, placed more precisely.
The forehead muscle is now understood to be bidirectional, divided by what anatomists call the line of convergence: below that line it elevates the brow, above it, it pulls the hairline down. A 2026 study of 41 participants tested a "super-high" technique — two midline points in the upper fifth of the forehead at 1.5 to 2 units per point — and reported forehead lines improved 51% at rest and 63% in movement, with brow position essentially unchanged, brow movement preserved, and no brow ptosis in any participant. It is the mechanism behind the FDA's own instruction, explained.
A 2026 review describes approaching the frontalis, glabella and orbicularis oculi as a single dynamic complex rather than three separate treatment areas — injecting the lower third of the frontalis with lateral extension into the orbicularis while sparing the middle third. The evidence is a small case series, so it is a framework rather than a protocol, but it is the same logic that governs full-face Botox® and strategic injection for facial harmony.
A 2025 anatomical paper dissected three cadavers and found the relevant orbicularis fibres sit specifically at the edge of the superolateral orbital rim. In an accompanying single case, a 1-unit intradermal injection located by ultrasound produced easier eye opening and brow elevation at four weeks. One case is not evidence of efficacy, and it should be presented as a proposal rather than a standard — but it is a striking counterpoint to the idea that a brow lift needs tens of units.
Before-and-after photographs are useful when they are honest about what they show. A good brow lift comparison is taken at the same distance, in the same light, with the face at rest and the camera at brow height — and the difference it shows is a few millimetres at the outer brow, a slightly larger visible eyelid, and a softer glabella. It is not a different face.
What patients tend to notice first is not brow height at all. It is that the eye reads as more open, which is measurable: the 2026 series above recorded the exposed eyelid area up roughly 12% by day 30, and a separate 2026 case series found that standard on-label treatment of the glabellar and crow's-feet areas made eyes read as visibly larger to injectors, to independent observers, and to the patients themselves.
For providers, the practical lesson is to photograph before every treatment, at rest and at maximum brow elevation, and to note baseline brow position and asymmetry in the chart. Without that baseline, neither you nor the patient can judge what the treatment did.
Get self-paced access to a real IAPAM Botox® module — watch step-by-step injection technique, follow along with our physician instructors, and claim 1 AMA PRA Category 1 CME when you finish.
What’s Inside Your Free Module
Eligibility: MD/DO, NP, APRN/CRNA, PA, DMD/DDS, RN
Enter your details and we’ll email your access link.
No. A randomized controlled trial of 45 patients (90 eyebrows) found that two weeks after upper-face botulinum toxin the brow sat lower at every measured position except the outer edge, which sat higher. The reliable effect is a lift of the brow tail. Treating the forehead relaxes the only muscle that holds the rest of the brow up, so the inner and central brow tend to settle rather than rise.
It depends entirely on which approach is used. A targeted lateral brow lift is published at roughly 8 to 10 units placed just below the outer eyebrow. The often-quoted 20 to 40 unit figure comes from a trial that injected the glabella alone across seven sites, where 20 to 40 units raised the brow and 10 units actually lowered it. There is no single correct number, and dosing should be assessed on the individual rather than looked up.
No. BOTOX® Cosmetic is FDA-approved for four cosmetic uses in adults: moderate to severe glabellar lines, lateral canthal lines, forehead lines and platysma bands. Using botulinum toxin to reposition the eyebrow is an established off-label use. Off-label prescribing is legal and common in aesthetic medicine, but the patient should be told and it should be documented.
Most patients see change in the brow within one to two days, and the effect of a glabellar-led lift continues building for about twelve weeks before fading. Overall duration is usually three to four months, though a small lateral dose in a mobile muscle can be shorter. Retreatment intervals should not be closer than three months.
Sometimes, and only partly. If the hooding comes from a low-sitting brow tail, relaxing the muscle that pulls that tail down can open the eye a few millimetres. If the hooding comes from excess upper eyelid skin, botulinum toxin cannot remove skin and the honest answer is that this is a surgical question. Treating a patient who depends on their forehead muscle to hold the eyelid up can make hooding worse.
The main risks are a dropped brow, a dropped eyelid and an over-peaked outer brow known as a Spock or Mephisto brow. In BOTOX® Cosmetic trials, brow ptosis occurred in 2 percent and eyelid ptosis in 2 percent of forehead-line patients, and eyelid ptosis in 3 percent of glabellar patients. Ordinary side effects include bruising, tenderness, headache and temporary asymmetry. All botulinum toxin products carry a boxed warning about the effects of the toxin spreading beyond the injection site.
The brow is the area where small errors are most visible and most avoidable. Knowing which muscle sits where, how far above the orbital rim to stay, and why the forehead is never treated in isolation is the difference between a patient who looks rested and one who books a corrective appointment.
IAPAM has been training licensed healthcare professionals for more than 20 years, with hands-on injection practice on live models under board-certified physician instructors and AMA PRA Category 1 CME. If you want to build that foundation, start with IAPAM’s hands-on Botox® training — or claim your free module and 1 CME above and see how we teach before you commit.
Explore Botox® Training & Certification
Disclaimer: This guide is for informational and educational purposes only and does not constitute medical advice. Treatment plans, injection techniques, and dosing must be tailored to each patient by a qualified, licensed provider. Always follow product labeling, your scope of practice, and your state medical and nursing board regulations.
The history of Botox® began when a toxin called Botulin was first discovered connected to a very rare form of a paralytic illness.
Starting an aesthetic practice can feel overwhelming — but it doesn’t have to be. These four essential pillars will guide you toward building a successful, independent, and sustainable aesthetic practice with confidence.
New to injecting Botox®? This guide walks you through the most common mistakes—and how to avoid them—so you can deliver safe, natural-looking results your patients will love.
Free Clinical Resource
A practical training resource for providers who want a stronger clinical foundation for Botox® treatment conversations and injection planning.
Click the guide cover to request your free copy.
Looking for hands-on or online Botox® training options? Explore IAPAM’s Botox training programs →
Terms and conditions apply. Offer expires October 31.